Transcript Oral Communication

Elenco Oral Communication
ID
N. pgm
Title
07/06/2016
Presenting Author
10.15 - 11.55
Community I
Chairs: G.M. Corbelli, L. Rancilio
89
OC 1
Insight into HIV/AIDS and STDs among Italian high-school teens: an unceasing need to inform and to
protect
276
OC 2
Would they benefit from PrEP? An analysis of men who have sex with men seeking post-exposure Gabriella De Carli, Roma
prophylaxis following sexual exposures at risk of HIV infection
245
OC 3
Saliva Test for the general public: following the objectives of Unaids
Giorgia Fracca, Milano
155
OC 4
BLQ Checkpoint: data from first six months of activity
Sandro Mattioli, Bologna
337
OC 5
HIV rapid testing targeting MSM: some issues towards the improvement of efficacy in a community- Paola Guarino, Padova
based testing initiative of Arcigay in 11 cities funded by the Unione delle Chiese Metodiste e Valdesi
49
OC 6
HIV Toolkits for migrants: tailored information on their right to health, HIV prevention, testing, Maria Luisa Cosmaro,
treatment and care in Italy, given by migrants themselves through video tutorials
Milano
123
OC 7
Transmission of HIV through sexual contact in Italian Criminal Law
274
OC 8
Villa Maraini Foundation’s HIV/HCV Care Cascade Among Hard to Reach Injection Drug Users in Rome: Elisabetta Teti, Roma
Meet, Test and Treat
07/06/2016
10.15 - 11.55
Coinfections
Renato Maserati, Pavia
Francesca Manfredi, Parma
Chairs: R. Maserati, M. Zaccarelli
342
OC 9
Evolution and determinants of the prevalence of HCV infection and HCV genotype distribution among Barbara Rossetti, Siena
HIV-infected patients entering in care between 1997 and 2015 in Italy: data from a prospective
nationwide cohort (ICONA)
14
OC 10
The TM6SF2 E167K variant is an independent predictor of severe steatosis in HIV patients with chronic Caterina Sagnelli, Napoli
hepatitis due to HCV-genotype non 3
219
OC 11
Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir Ribavirin in Patients with HIV-HCV Coinfection: Real
Life Interim Analysis of an Italian Multicentre Compassionate Use Program
Elisabetta Teti, Roma
338
OC 12
SOF/VEL single tablet regimen in HCV mono-infected and HIV/HCV co-infected patients: comparison of
efficacy and safety data from phase 3 clinical trials
Giustino Parruti, Pescara
107
OC 13
Efficacy of Directly Acting Antivirals in HCV-3 Patients with advanced Fibrosis: An interim analysis of the Giuliano Rizzardini, Milano
Lombardia Regional Network for Viral Hepatitis
221
OC 14
Clinical and virological characteristics of HIV and HCV coinfected versus HCV monoinfected patients: real
life evaluation in PITER and ICONA/HepaICONA cohorts
Barbara Coco, Cisanello
(PI)
207
OC 15
HPV infection in oral cavity of HIV-positive men: prevalence and predictors
Anna Rosa Garbuglia,
Roma
Minilecture: Coinfection in People Living with HIV: remember TB
Alberto Matteelli, Brescia
07/06/2016
14.20 - 15.45
Hepatitis I
Chairs: R. Bruno, G. d'Ettorre
38
OC 16
HBV genetic evolution in HBsAg can constrain HDV replicative potential
Luna Colagrossi, Roma
187
OC 17
Immunosuppression-driven HBV Reactivation in Patients with Resolved HBV Infection Correlates with a
Relevant Risk of Evolution Towards Active Chronic Infection and Death
Arianna Battisti, Roma
72
OC 18
Direct-acting antivirals (DAA) in HCV-infected and HCV/HIV co-infected patients: real-life safety and
efficacy
Francesca Binda, Milano
145
OC 19
Adherence to EASL recommendations significantly increased treatment response in 872 patients with
hepatitis C treated with combinations of oral antivirals
Massimo Puoti, Milano
179
OC 20
Influence of ITPase activity on decreases of hemoglobin during treatment with Interferon-free DAA- Stefania De Pascalis,
based and ribavirin in HCV-related cirrhosis
Napoli
294
OC 21
Effectiveness of Simeprevir regimens for Hepatitis C in real practice: results from the STIly Italian Barbara Menzaghi, Busto
observational study
Arsizio VA
193
OC 22
Liver microRNA hsa-miR-125a-5p may exert an oncosuppressor effect on hepatocellular carcinoma (HCC)
07/06/2016
14.20 - 15.45
Clinical HIV I
Lorenzo Onorato, Napoli
Chairs: A. Di Biagio, V. Vullo
370
OC 23
Prevalence and effect of polypharmacy on clinical outcome in people living with HIV: a 10-year follow up
study
Giovanni Guaraldi, Modena
330
OC 24
Feasibility, Acceptability and Tolerability of Peri-Conception Antiretroviral Pre-Exposure Prophylaxis
(PrEP-C) in HIV-Serodiscordant Couples
Gabriella De Carli, Roma
377
OC 25
Tolerability of different antiretroviral regimens prescribed as HIV Post-Exposure Prophylaxis
Vincenzo Puro, Roma
101
OC 26
Are Italian people aware of PEP and TasP? A survey among a large sample of people living with
HIV/AIDS, non-HIV positive high risk heterosexual people and non-HIV positive MSM
Gabriele Prati, Cesena
158
OC 27
Adherence to cART in a large single-center clinical cohort
Elisa Di Filippo, Bergamo
Minilecture: Pharmacokinetic correlates of effective cART
Andrea Calcagno, Torino
07/06/2016
302
OC 28
Agg.al 27/05/16
14.20 - 15.45
Complication of cART
Chairs: M. Borderi, P. Bonfanti
Exercise Stress Testing for Reduced Coronary Reserve Detection in Asymptomatic HIV-infected Subjects Vincenzo Spagnuolo,
with Cardiovascular Risk Factors: the CORDIS Study
Milano
1
Elenco Oral Communication
ID
N. pgm
Title
Presenting Author
288
OC 29
Changes with menopause in the distribution of a frailty index (FI) in HIV infected women
226
OC 30
Evolution of comorbidities among HIV patients in 2004 and 2014: a cross-sectional analysis from the Alessandro Cozzi Lepri,
Italian ICONA Foundation study cohort
London UK
303
OC 31
Impact of HIV infection on toxicity and outcome of non-Hodgkin lymphoma treatment in the Alessandra Bandera,
antiretroviral therapy era
Monza
27
OC 32
Excess mortality with non-AIDS-defining cancers among Italian people with AIDS in the late Saverio Virdone, Aviano
antiretroviral therapy era
(PN)
Stefano Zona, Modena
Minilecture: Frailty: virus, ART or lifestyle?
07/06/2016
15.50 - 17.25
Giovanni Guaraldi, Modena
Hepatitis II
Chairs: S. Babudieri, T. Quirino
40
OC 33
HBsAg immune-escape Mutations and Stop-Codons, Circulating among European HBV-chronically Luna Colagrossi, Roma
infected patients can impact on HBV transmission and disease progression
138
OC 34
Virological failures to Direct Acting Antivirals (DAA) in a real life setting show frequent resistance Velia Chiara Di Maio, Roma
associated variants and may require re-treatment with unconventional regimens
170
OC 35
The elderly and DAAs: constraint or challenge?
Claudia Fabrizio, Bari
51
OC 36
Striking gender differences in emotional intelligence among HCV cirrhotic patients
Martina Spaziante, Roma
292
OC 37
Resistance-Associated Variants of Hepatitis C at baseline and failure during DAA-based therapy
Alessia Lai, Milano
98
OC 38
Sofosbuvir and Ribavin for difficult to treat HCV-2 patients: improved SVR rates with prolonged therapy
Cristina Rossi, Treviso
Minilecture: HCV infection in the migrant population
Nicola Coppola, Napoli
07/06/2016
15.50 - 17.25
Clinical HIV II
Chairs: A. Cossarizza, S. Rusconi
173
OC 39
Results of Italian Network of ACuTe HIV InfectiON (INACTION) retrospective study
Antonio Muscatello, Monza
357
OC 40
Virological efficacy of two treatment strategies for Primary HIV Infection (PHI): comparison of (TDF
+FTC) associated with either Darunavir/Ritonavir+Raltegravir or Dolutegravir
Carmela Pinnetti, Roma
218
OC 41
Virological response and immunological recovery of HIV-1 infected patients starting a first line regimen Maria Mercedes Santoro,
with plasma HIV-1 RNA >500,000 copies/mL in clinical practice
Roma
184
OC 42
Drop in CD4+ counts below 200 cells/µL after reaching (or starting from) values higher than 350 cells/µL
in HIV-infected patients with virological suppression
329
OC 43
The Impact of Age at HIV Diagnosis on CD4/CD8 Ratio and Multimorbidity in Elderly HIV-positive Andrea Calcagno, Torino
Patients
234
OC 44
Impact of 48 week Atazanavir/Ritonavir Plus Lamivudine Dual Therapy on HIV-DNA Level: a sub-study of
ATLAS-M Trial
Francesca Lombardi,
Roma
Minilecture: Immunoreconstitution and inflammation during cART: good and bad news
Alessandra Bandera,
Monza
08/06/2016
10.15 - 11.55
Immunology
Nicola Gianotti, Milano
Chairs: A. De Maria, G. Poli
320
OC 45
Lack of normalization of inflammatory soluble markers in HCV cirrhotic and non cirrhotic patients Claudia Mascia, Roma
undergoing DAA therapy
287
OC 46
Increased osteoclastogenesis in HIV positive cART-treated patients with reduced Bone Mineral Density Elvira Stefania Cannizzo,
(BMD): role of Suppressor of Cytokine Signaling-1 (SOCS-1) and Tumor Necrosis Factor Receptor- Milano
Associated Factor 6 (TRAF-6)
92
OC 47
Age-dependent dysregulation of IFN response
antiretroviral therapy
293
OC 48
Neuroasymptomatic cerebrospinal fluid (CSF) viral escape is associated to increased intrathecal immune Carmela Pinnetti, Roma
activation but not with CSF signs of neuronal injury
109
OC 49
A high rate of CD56bright NK cells is associated with poor CD4+ T cell reconstitution in HIV-1-infected Erica Giuliani, Roma
immunological non responders on suppressive antiretroviral therapy
18
OC 50
β-arrestins specific siRNA inhibits CCR5 signalosome mediated by human serum antibodies in long-term Assunta Venuti , Milano
HIV infected subjects
328
OC 51
Unconventional T-cells in Chronic Hepatitis B (CHB) Patients on Long-Term Suppressive TDF Treatment Camilla Tincati, Milano
prior to and following a PEG-INF Add-On Strategy
in HIV-1 infected patients on long-term combination Carolina Scagnolari, Roma
Minilecture: Immunology and HIV disease: what a clinician should absolutely consider
08/06/2016
10.15 - 11.55
Clinical HIV III
Giulia Marchetti, Milano
Chairs: A.M. Cattelan, L. Sighinolfi
174
OC 52
Z-Score Index to Early Detect and Monitor HIV Brain Damage Using EEG LORETA
352
OC 53
High rate of asymptomatic vertebral fractures in a cohort of HIV-Infected patients undergoing Alessandro D'Avino, Roma
quantitative morphometric assessment
105
OC 54
A co-morbidity approach to cART: the CRISIS study
Franco Maggiolo, Bergamo
378
OC 55
HIV-positive subjects treated with single tablet regimens (STR) when ART-naïve in clinical practice
Alessandro Cozzi-Lepri,
London UK
Agg.al 27/05/16
Elisabetta Teti, Roma
2
Elenco Oral Communication
ID
N. pgm
Title
312
OC 56
Dolutegravir (DTG)-containing regimens after failing to raltegravir (RAL) or elvitegravir (EVG): durability Stefano Rusconi, Milano
and virological response
236
OC 57
Virologically suppressed patients switching therapy with PBMCs resistance and insufficient previous
virological control have a higher risk of experiencing virological rebound
Daniele Armenia, Roma
148
OC 58
Outcomes of second line antiretroviral therapy in HIV-infected patients: data from the ICONA cohort
Antonio Di Biagio, Genova
Minilecture: HIV-associated lymphoma: epidemiology and management today
Antonella Cingolani, Roma
08/06/2016
Presenting Author
13.40 - 15.10
Basic science and clinical virology
Chairs: S. Buttò, L. Lopalco
233
OC 59
Dynamics and phylogenetic relationships of HIV-1 transmitted drug-resistance according to subtype in
Italy over the years 2000-2014
175
OC 60
PD-1 and CTLA-4-expressing cells are key contributors to viral persistence in ART-suppressed SIV- Colleen McGary, Atlanta
infected rhesus macaques
USA
372
OC 61
Pre-ART HIV-1 DNA correlates with viro-immunologic status and outcome in patients with 1st-line ART
Francesca CeccheriniSilberstein, Roma
199
OC 62
Defective proviruses accumulate early during HIV infection and show no decay during long-term cART
Francesco Roberto
Simonetti, Milano
108
OC 63
Analysis of the mRNA expression of DNA damage response genes in HIV infected patients
Laura Mazzuti, Roma
379
OC 64
Intestinal dendritic cells and macrophages : what’s their role in HIV infection?
Mariangela Cavarelli,
Fontenay-aux-Roses F
121
OC 65
Probiotics supplementation modulates type I and II IFN response in treated HIV-1 positive patients with
suppressed viremia
Giuseppe Corano Scheri,
Roma
08/06/2016
13.40 - 15.10
Community II
Lavinia Fabeni, Roma
Chairs: M. Cascio, S. Marcotullio
201
OC 66
Human dignity principle in the Italian Constitution: a value to be achieved in health care policies
Monica Cappelletti, Parma
96
OC 67
HIV disclosure: how, when, to whom
Annalisa Perziano, Torino
58
OC 68
A budget impact analysis of the novel therapeutic regimens for the treatment of HCV infected patients in
the Lombardy Region
Elisabetta Garagiola,
Castellanza VA
156
OC 69
ChemSex: knowledge and behaviours among Italian MSM
Giulio Maria Corbelli, Roma
34
OC 70
Psychiatric issues in treating HCV positive inmates with DAAs: a new challenge
Roberto Ranieri, Milano
59
OC 71
The management of HIV+ patients suffering from neurocognitive impairment: determinants of cost
Emanuela Foglia,
Castellanza VA
10
OC 72
What recently infected people think about HIV? Results from a web survey for naïve patients
Simone Marcotullio, Roma
08/06/2016
13.40 - 15.10
Clinical HIV IV
Chairs: O. Armignacco, G. Madeddu
333
OC 73
A Multicenter Observational Study on the Efficacy and Metabolic Safety of Dolutegravir plus either Alberto Borghetti, Roma
TDF/FTC or ABC/3TC as a Simplification Strategy in HIV-1 Positive, Antiretroviral-experienced Patients
345
OC 74
Long term safety and tolerability of dual therapy with maraviroc (MVC) + darunavir/ritonavir (DRV/r) in
virosuppressed HIV infected patients with R5 viral tropism
76
OC 75
Durability of rilpivirine- and integrase inhibitor-based simplification regimens in virologically suppressed Nicola Gianotti, Milano
HIV-Infected patients
104
OC 76
A dual lamivudine + dolutegravir cART as maintenance strategy in patients with suppressed HIV-RNA
Franco Maggiolo, Bergamo
353
OC 77
Efficacy and Safety of Lamivudine-Dolutegravir in a Multicenter Cohort of HIV-infected, Virologically
Suppressed Patients
Gianmaria Baldin, Roma
100
OC 78
Durability of Dolutegravir (50 mg BID) including regimens in INI-resistant failing HIV-1 infected subjects Antonella Castagna, Milano
in Italy: data from the PRESTIGIO National Database
Minilecture: Has adherence a critical role nowadays?
08/06/2016
13.40 - 15.10
HIV Epidemiology
Barbara Rossetti, Siena
Adriana Ammassari, Roma
Chairs: M. Lichtner, S. Lo Caputo
73
OC 79
Determinants of ‘HIV-risk unawareness’ at the first diagnosis: analysis from National HIV Surveillance, Maria Dorrucci, Roma
2010-2014
47
OC 80
Estimates of the number of people with undiagnosed HIV in need of antiretroviral therapy (ART) in Italy Vincenza Regine, Roma
using the ECDC HIV modelling tool
239
OC 81
Forecasting the Evolution of HIV Epidemics in Italy: Benefits of Early Treatment
Marco Franzetti, Milano
189
OC 82
Second national census among people diagnosed with HIV and in care in Italy in 2014
Mariangela Raimondo,
Roma
321
OC 83
An estimate of the continuum of HIV care in Italy in 2014 using surveillance and cohort data
Alessia Mammone, Roma
358
OC 84
New HIV infections in Apulia from 2011 to 2015 : epidemiological aspects, management and retention in
care
Sergio Lo Caputo, Bari
335
OC 85
Multimorbidity, Polypharmacy and Antiretrovirals’ Prescription in The GEPPO cohort (GEriatricPatients Giovanni Guaraldi, Modena
living with HIV/AIDS)
Agg.al 27/05/16
3